Local view for "http://purl.org/linkedpolitics/eu/plenary/2010-11-22-Speech-1-997"
Predicate | Value (sorted: default) |
---|---|
rdf:type | |
dcterms:Date | |
dcterms:Is Part Of | |
dcterms:Language | |
lpv:document identification number |
"en.20101122.17.1-997"2
|
lpv:hasSubsequent | |
lpv:speaker | |
lpv:spoken text |
"Information regarding consumer products has become essential. Information on medicines is especially sensitive. One important distinction which has to be made is between information and advertisement. The European Parliament, in discussing this report, is making safeguards where medicines are concerned. One instance is that printed matter has to be submitted to the European Medicines Agency (EMA) 90 days in advance for analyses before being forwarded to consumers. One important element which is not being addressed is information on prices. During this legislature, I have insisted on the high prices of medicines in Malta when compared to the same medicines elsewhere in the European Union. The difference in price is not minimal but unbelievable. The cost of some medicines in Malta is double or even more than the cost in Europe. When I submitted questions to the Commission on the subject, they always indicated that this is an issue for the national government. I strongly believe that the EMA should not only act as a shield for consumers in relation to information on medicines, but when consumers are being blatantly overcharged for medicines and national governments are unable to tackle the issue, the EMA should have the ability to address the issue."@en1
|
lpv:spokenAs | |
lpv:unclassifiedMetadata |
Named graphs describing this resource:
The resource appears as object in 2 triples